Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

France
Israel
Italy
Spain
EuroGeBeta
European network on genetics, pathophysiology and translational research into rare pancreatic beta-cell insufficiency diseases

Project Coordinator

CNRS Genomic and Molecular Physiology of Metabolic Diseases Biologie de Lille-Institut
Lille
France

Partners

Antonio Luis Cuesta-Munoz IMABIS Foundation Hospital Carlos Haya Center for the Study of Pancreatic B-Cell Disease Malaga, Spain
Christine Bellane-Echantelot AP.MP Groupe Hospitalier Pitié-Salpêtrière Department of Genetics Paris, France
Fabrizio Barbetti Bambino Gesù Pediatric Hospital, IRCCS Laboratory of Molecular Endocrinology and Metabolism Rome, Italy
Michel Polak Hôpital Necker - Enfants Malades ISERM U845 Pediatric Endocrinology Paris, France
Moshe Phillip Schneider Children Medical Center Lea Shafer Institute of Endocrinology and Diabetes Petah Tikva, Israel

Publications of the EuroGeBeta project

Major results of the project

Rare monogenic disorders of pancreatic -cell insufficiency cause non autoimmune diabetes mellitus in newborns, in infants/children or in adolescents and young adults. A broad spectrum of often severe clinical conditions have been recognized as neonatal diabetes mellitus (NDM), non autoimmune monogenic diabetes of infancy (MDI), or as maturity-onset diabetes of the young (MODY). Specific mechanisms of -cell dysfunction have been identified in those conditions, which have improved our views of the control of insulin secretion in humans, and had a great clinical impact in the patients care and genetic counseling of families. However, in numerous patients with isolated diabetes or presenting with extra-pancreatic  features, the genetic subtype of the -cell defect was still unelucidated at the beginning of our project, suggesting that unrecognized additional defects in important pathways in the insulin-secreting -cell remain to be identified. Within the EuroGeBeta consortium, gathering together six partners in France, Italy, Spain and Israel with complementary expertises in paediatric endocrinology, in genetic diagnosis and counselling, in human genetics and genomic research applied to metabolic diseases, our objectives were: 1/ to establish a transnational European cohort of patients (and families) with non auto-immune neonatal/infancy/childhood -cell insufficiency; 2/ to carry out state-of-the-art genomic studies (using genome-wide SNP-arrays and next-generation sequencing [NGS]) to unravel novel genes and cellular pathways controlling insulin secretion; 3/ to characterize the clinical features and pathophysiological consequences associated with the novel causal mutations; and 4/ to establish an integrated multidisciplinary network for molecular diagnosis, genetic counselling and patient care, with the aim to transfer when possible the new results from basic genetic research into clinical practice. Expected perspectives of our project are to provide a nosological reappraisal of these disorders and their clinical outcomes, and to propose a genetic counselling and personalized treatment based on genomic medicine.

After the three years completion of the project, our major results are:
1/ Establishment of an European cohort of patients with NDM/MDI/MODY, with extensive clinical data for phenotype description and biological samples for genetic/metabolic studies.
2/ Identification of several genetic etiologies (both known and novel subtypes) in patients with NDM/MDI/MODY, with carefull clinical evaluation and impact on treatment; and identification of patients tested negative for the know genes (involved in NDM/MDI/MODY), who are eligible for further genetic studies within the consortium.
3/ Implementation and validation of several high throughput genomic research tools (whole exome sequencing (WES) combined with NGS, SNP-array genotyping) with appropriate analysis pipelines; proof-of-concept that the WES analysis is a powerful approach for discovering novel causal mutations in specific forms of diabetes. Five papers reporting novel mutations (in KCNJ11, ABCC8, GATA6 and MNX1) in five families have been published.
4/ Partners 1 and 2 recently developed new amplicons-sequencing methods combined with NGS for a comprehensive, accurate and cost-effective genetic screening of NDM/MDI/MODY patients; these new diagnostic methods have been fully validated for their use in routine genetic testing offering new perspectives of genetic diagnosis and clinical translation towards the patients.
5/ Description of genotype-phenotype correlations in patients according to genetic subtypes, with evidence of clinical variability within specific subtypes. Several papers on these clinical aspects have been published: on the metabolic control and follow-up of sulphonylurea therapy in patients with a KATP channel mutation, or on a novel frameshift GATA6 mutation associated with NDM/MDI, pancreas hypoplasia/agenesis and heart defects.
6/ The multidisciplinary approach of the EuroGeBeta consortium based on integrated genomic and clinical research resulted in a better management of the therapeutic options in the young studied patients, as well as in a more personalized genetic counselling.

E-Rare 2012 - Created by Toussaint Biger